Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 5,237 | 1,168 | 2,270 | 512 | 391 |
| Cost of Goods | 176 | 204 | 985 | 125 | 112 |
| Gross Profit | 5,061 | 964 | 1,285 | 387 | 279 |
| Operating Expenses | 11,633 | 29,406 | 9,113 | 7,592 | 7,441 |
| Operating Income | -6,396 | -28,238 | -6,843 | -7,080 | -7,050 |
| Interest Expense | 0 | 0 | -1 | 0 | 2 |
| Other Income | -697 | 227 | -2,004 | 2,115 | 5,604 |
| Pre-tax Income | -7,093 | -28,011 | -8,846 | -4,965 | -1,448 |
| Income Tax | N/A | N/A | -1,012 | -169 | 0 |
| Net Income Continuous | -7,093 | -29,192 | -7,834 | -4,796 | -1,448 |
| Minority Interests | -6 | -200 | -11 | -8 | -32 |
| Net Income | $-7,087 | $-28,992 | $-7,823 | $-4,788 | $-1,416 |
| EPS Basic Total Ops | -0.04 | -0.17 | -0.05 | -0.03 | -0.01 |
| EPS Basic Continuous Ops | -0.04 | -0.18 | -0.05 | -0.03 | -0.01 |
| EPS Diluted Total Ops | -0.04 | -0.17 | -0.05 | -0.03 | -0.01 |
| EPS Diluted Continuous Ops | -0.04 | -0.18 | -0.05 | -0.03 | -0.01 |
| EBITDA(a) | $-6,218 | $-28,052 | $-6,645 | $-6,873 | $-6,754 |